Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

Updated COPD-X guide reflects stronger evidence for triple therapy

As-needed ICS now available on PBS for mild asthma

Osimertinib could be new standard of care for EGFRm NSCLC

CF patients with liver disease at high risk of bone loss and diabetes

Pulmonary complications and mortality high in surgical patients with COVID-19

Asthma

Tiotropium to be listed on PBS for children with severe asthma

By Michael Woodhead

22 Feb 2019

The long-acting muscarinic antagonist (LAMA) tiotropium inhaler (Spiriva Respimat) will be listed on the PBS for children age six and over with severe asthma from 1 March. Federal Minister for Health Greg Hunt announced the listing on 21 February, saying it would extend access from adults to allow up to 30,000 children with asthma. The ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories